Randomized single-blind trial of topical ketanserin for healing acceleration of diabetic foot ulcers
Arch. med. res
;
28(1): 95-9, mar. 1997. tab, ilus
Article
in English
| LILACS
| ID: lil-225203
RESUMEN
The objective of this study was to determine the efficacy of topically applied ketanserin for healing acceleration of diabetic foot ulcers. From august 1993 to september 1994, 140 NIDDM patients entered a randomized single-blind trial of topical ketanserin (Sufrexal, Janssen Pharmaceuticals; n=69) vs. normal saline (labeled here as placebo; n=71). All patients were subjected to surgical debridement of necrotic tissue and lavage with normal saline. Wound were <100 cm² in area. Persons with NIDDM and foot ulcers Wagner 2 and 3 with a median of 8 (interquartile range 4 -26) weeks duration were included. Ulcer area was measured at 0, 4, 8 and 12 weeks. The groups were similar in age, sex, years of diabetes duration, obesity, ulcer Wagner type, number of previous amputations and surgical debridements during this hospital stay. Average percent reduction in ulcer area at 12 weeks was 87 percent for ketanserin vs. 63 percent for placebo (p<0.001). The regression equations for the leastsquares fit to the area (y) against time (x) data points were y = 43.46-3.181x(r=0.995) for ketanserin and y= 39.46-2.016x(r=-0.999) for placebo (p<0.01). The 95 percent confidence limits for slopes were -3.181 ñ 0.98 and -2.016ñ0.15. Thus, average daily reduction in ulcer area was 4.5 mm²/day for ketanserin vs. 2.88 mm²/day for placebo. In clnclusion, topical ketanserin significantly accelerated wound healing in diaetic neurothrophic foot ulcers when applied as part of a comprehensive healing program
Search on Google
Index:
LILACS (Americas)
Main subject:
Serotonin Antagonists
/
Wound Healing
/
Ketanserin
/
Diabetic Foot
Type of study:
Controlled clinical trial
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
Arch. med. res
Journal subject:
Medicine
Year:
1997
Type:
Article
Similar
MEDLINE
...
LILACS
LIS